Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc.
(Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump
with Control-IQ technology is now fully compatible with both the
Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM)
Systems. Tandem Mobi, the world’s smallest, durable automated
insulin delivery (AID) system1, launched in the United States
earlier this year.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240529812588/en/
Tandem Mobi insulin pump from Tandem
Diabetes Care is now compatible with Dexcom G7 Continuous Glucose
Monitoring (CGM) System. (Photo: Business Wire)
Tandem is now the only company that offers people living with
diabetes two insulin pump options that connect with both Dexcom G6
and Dexcom G7, providing more choice in how they manage their
diabetes. Tandem’s #1-rated2 t:slim X2™ insulin pump was the first
AID system to feature Dexcom G7 integration, as announced in late
2023.
Tandem will email all Tandem Mobi users in the United States
over the coming weeks, when their software update is available,
with instructions on how to add the new feature free of charge by
remote software update. Tandem Mobi pumps pre-loaded with the
updated software are now shipping to new customers.
“Choice is a hallmark of our offerings, and we’ve proven this
commitment with the expansion of our insulin pump portfolio and
extended CGM compatibilities,” said John Sheridan, president and
chief executive officer of Tandem Diabetes Care. “With this
integration, we’re providing more flexibility for our customers and
continuing our decade-long partnership with Dexcom to bring
innovative and discrete solutions to people living with
diabetes.”
Tandem Mobi is small enough to be worn almost anywhere3,
including a coin pocket, providing users with more discretion,
comfort, and options for how they manage their diabetes. Powered by
Control-IQ technology, which has demonstrated in real-world studies
improved time in range overnight and during the day4, Tandem Mobi
connects with Dexcom G7 or Dexcom G6 to predict glucose levels 30
minutes in advance and automatically adjusts insulin, if needed, to
help prevent highs and lows.
With the integration of Dexcom G7, Tandem Mobi users can also
experience:
- More time in closed loop with Dexcom G7’s 30-minute sensor
warm-up time – faster than any other CGM on the market.5
- Additional discretion with Dexcom G7’s low-profile, all-in-one
wearable.
“As the leader in connectivity, Dexcom has been the CGM of
choice for the development of AID systems for over a decade,” said
Jake Leach, executive vice president and chief operating officer at
Dexcom. “We are proud to offer people with diabetes the ability to
use Dexcom G7, our smallest and most accurate CGM, with Tandem Mobi
to create a seamless user experience.”
For more information about Tandem Mobi and how to start the
order process, please visit www.tandemdiabetes.com/mobi.
- As of May, 2024. Data on file, Tandem Diabetes Care.
- dQ&A Q1 2024 US Diabetes Patient Voice Report.
- The pump should not be placed more than 12 inches (30.5 cm)
above the infusion site. Doing so may result in over delivery of
insulin.
- All published clinical trials and real-world studies of
Control-IQ technology to date are based on use of Dexcom G6 CGM
with the Tandem t:slim X2 insulin pump.
- Dexcom G7 can complete warmup within 30 minutes, whereas other
CGM brands require up to an hour or longer.
About Tandem Diabetes Care
Tandem Diabetes Care, a global insulin delivery and diabetes
technology company, manufactures and sells advanced automated
insulin delivery systems that reduce the burden of diabetes
management, while creating new possibilities for patients, their
loved ones, and healthcare providers. The Company’s pump portfolio
features the Tandem Mobi system and the t:slim X2 insulin pump,
both of which feature Control-IQ advanced hybrid closed-loop
technology. Tandem Diabetes Care is based in San Diego, California.
For more information, visit tandemdiabetes.com.
Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2
#TandemMobi and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at
www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at
https://www.linkedin.com/company/tandemdiabetes.
© 2024 Tandem Diabetes Care, Inc. All rights reserved. Tandem
Diabetes Care, the Tandem logo, Control-IQ, t:slim X2, and Tandem
Mobi are either registered trademarks or trademarks of Tandem
Diabetes Care, Inc. in the United States and/or other countries.
Dexcom, Dexcom G6, Dexcom G7, and any related logos and design
marks are either registered trademarks or trademarks of Dexcom,
Inc. in the United States and/or other countries. iPhone is a
trademark of Apple Inc., registered in the U.S. and other
countries. All other third-party marks are the property of their
respective owners.
Responsible Use of Control-IQ technology
Control-IQ technology does not prevent all highs and lows. Users
must still bolus for meals and actively manage their diabetes.
Visit tandemdiabetes.com/responsible-use for additional important
safety information.
Important Safety Information
RX ONLY. Indications for Use: Tandem Mobi
system: The Tandem Mobi insulin pump with interoperable
technology (the pump) is intended for the subcutaneous delivery of
insulin, at set and variable rates, for the management of diabetes
mellitus in persons requiring insulin. The pump is able to reliably
and securely communicate with compatible, digitally-connected
devices, including automated insulin dosing software, to receive,
execute, and confirm commands from these devices. The pump is
intended for single patient, home use and requires a prescription.
The pump is indicated for use in individuals 6 years of age and
greater. Control-IQ technology:
Control-IQ technology is intended for use with compatible
integrated continuous glucose monitors (iCGMs, sold separately) and
alternate controller enabled (ACE) pumps to automatically increase,
decrease, and suspend delivery of basal insulin based on iCGM
readings and predicted glucose values. It can also deliver
correction boluses when the glucose value is predicted to exceed a
predefined threshold. Control-IQ technology is intended for the
management of Type 1 diabetes mellitus in persons 6 years of age
and greater. Control-IQ technology is intended for single patient
use. Control-IQ technology is indicated for use with NovoLog or
Humalog U-100 insulin.
WARNING: Control-IQ technology should not be used by anyone
under the age of 6 years old. It should also not be used in
patients who require less than 10 units of insulin per day or who
weigh less than 55 pounds.
Control-IQ technology is not indicated for use in pregnant
women, people on dialysis, or critically ill patients. Do not use
Control-IQ technology if using hydroxyurea. Users of a Tandem
insulin pump and Control-IQ technology must use the insulin pump,
CGM, and all other system components in accordance with their
respective instructions for use; test blood glucose levels as
recommended by their healthcare provider; demonstrate adequate
carb-counting skills; maintain sufficient diabetes self-care
skills; see healthcare provider(s) regularly; and have adequate
vision and/or hearing to recognize all functions of the pump,
including alerts, alarms, and reminders. The Tandem pump and the
CGM transmitter and sensor must be removed before MRI, CT, or
diathermy treatment. Visit tandemdiabetes.com/safetyinfo for
additional important safety information.
Forward-looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements relate to, among other
things, our ability to provide the software updates for current
Tandem Mobi customers and the Tandem Mobi pumps pre-loaded with
Dexcom G7 integration software. These statements are subject to
numerous risks and uncertainties, including our ability to start
and continue commercial-scale manufacturing of the Tandem Mobi
pumps pre-loaded with Dexcom G7 integration software, our ability
to operate and maintain a system to facilitate online training for
existing Tandem Mobi customers who upgrade their existing devices,
and the risk that we may encounter other challenges that may delay
the availability of Tandem Mobi pumps pre-loaded with Dexcom G7
integration software, as well as our ability to market, scale, and
maintain the systems, personnel, and infrastructure necessary to
support these integrations. These and other risks are identified
and described in greater detail under the “Risk Factors” heading of
our most recent Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q, and other documents filed with the Securities and
Exchange Commission. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this release. Actual results could differ materially
from those anticipated or projected in the forward-looking
statements. Tandem undertakes no obligation to update or review any
forward-looking statement in this press release because of new
information, future events, or other factors.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529812588/en/
Tandem Media Contact: 858-366-6900
media@tandemdiabetes.com
Tandem Investor Contact: 858-366-6900
IR@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
